Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Time to Sell?

Clearmind Medicine Inc. (NASDAQ:CMND) shares fell 4.8% on Wednesday . The stock traded as low as $0.95 and last traded at $1.00. 77,741 shares changed hands during trading, a decline of 91% from the average session volume of 877,723 shares. The stock had previously closed at $1.05.

Clearmind Medicine Stock Performance

The business’s fifty day moving average price is $1.02 and its 200-day moving average price is $1.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.72 and a quick ratio of 1.72. The stock has a market capitalization of $4.27 million, a PE ratio of -0.53 and a beta of 0.89.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Thursday, March 13th. The company reported ($0.24) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Clearmind Medicine stock. Citadel Advisors LLC raised its holdings in shares of Clearmind Medicine Inc. (NASDAQ:CMND) by 115.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,158 shares of the company’s stock after buying an additional 20,429 shares during the quarter. Citadel Advisors LLC owned about 0.89% of Clearmind Medicine worth $53,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 96.05% of the company’s stock.

Clearmind Medicine Company Profile

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.